See article, p. 1282.
Compared with younger patientswith melanoma, patients age 50 and older have worse prognoses and poorer responses to BRAF- and MEK-targeted therapies, even when controlling for tumor grade and stage at diagnosis. Alicea and colleagues found that the lipid secretome of dermal fibroblasts from older donors differed substantially from that of dermal fibroblasts from younger donors, containing significantly more ceramides, and melanoma cells grown in conditioned medium from aged dermal fibroblasts took up these lipids, increasing their total lipid concentration and the concentrations of specific ceramides secreted by the aged fibroblasts. Levels of the fatty acid transporter FATP2 were elevated in melanoma cells grown in conditioned medium from aged but not young dermal fibroblasts, in melanoma cells grown in aged but not young skin reconstructs, and in melanoma tumors grown intradermally in aged but not young mice. In vitro, treatment with a selective FATP2 inhibitor...
RSS Feeds